Adenocyte Information

An emerging medtech dedicated to help stop pancreatic cancer before it starts by allowing for the detection of still harmless, precancerous cells and early-stage tumors. A growing number of outstanding Medical Centers and Endoscopy Centers around the country are using LINFU® (Low-Intensity Non-Focused Ultrasound) to screen patients at increased risk for pancreatic cancer. While imaging generally detects abnormalities larger than 1 centimeter, LINFU enables physicians to identify significantly smaller, earlier-stage abnormalities. Our goal is to bring the same proactive screening strategy that dramatically reduced mortality in cervical and colon cancer to pancreatic cancer. How LINFU® Works An ultrasound probe is applied over the abdomen to gently enhance the natural exfoliation of cells lining the pancreatic ducts. A sample of fluid is then collected without entering the pancreas during a standard upper endoscopy and is sent to the laboratory for microscopic examination - on the cellular level - for the presence of still harmless but precancerous cells - known as dysplasia. Who should be screened? Most doctors recommend screening for adults at increased risk for pancreatic cancer, including those with: A pancreatic cyst, A first-degree relative (parent, sibling, or child) who had pancreatic cancer An inherited gene mutation linked to pancreatic cancer (e.g., BRCA1/2, Lynch Syndrome, PALB2, CDKN2A) Sudden, new-onset diabetes after age 50 accompanied by unexplained weight loss or persistent digestive issues A personal history of chronic pancreatitis or inherited pancreatic inflammation Follow our journey as we work to make pancreatic cancer preventable. For more information or inquiries about patient eligibility visit https://www.adenocyte.com/patients. Medical Centers and Endoscopy Centers who want to join our growing national network of testing sites, please visit https://www.adenocyte.com/contact.